December 12, 2022
After Sanofi failed to acquire, Amgen announced its plan to acquire Horizon Therapeutics.
Amgen announced that it has agreed to acquire Horizon Therapeutics. With the acquisition, Amgen expects to strengthen its innovative medicines portfolio by adding the medicines of Horizon Therapeutics. Amgen is also expecting the growth of Horizon Therapeutics medicines with the acquisition.
With the acquisition, Amgen gets a cash flow of nearly $10 billion which is expected to spend on capital allocation priorities, including investment in research.
Amgen has agreed to pay $116.50 per share, a premium of 48% to the closing price in Horizon Therapeutics' share on November 29, 2022, and a 20% premium to the closing price of December 9, 2022. The enterprise value of the acquisition is nearly $28.3 billion.
On December 11, Sanofi announced that it had ended the discussions with Horizon on acquisition.
Amgen also acquired Chemocentryx giving it access to the active antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis therapy Tavneos (avacopan).
05 October 2022
Pfizer completed the acquisition of Global Blood Therapeutics.
Pfizer announced that it had completed the acquisition of Global Blood Therapeutics, a biopharmaceutical company involved in developing therapies for sickle cell disease (SCD).
Also read: China Drug Approvals
Oxbryta (voxelotor) has received approval for treating sickle cell disease. GBT021601 (GBT601) and inclaclumab are the other investigational products in development for sickle cell disease and have received Orphan Drug and Rare Pediatric Disease designation.
Sickle cell disease is a life-long blood disorder characterized by hemolytic anemia, acute pain crises, and progressive end-organ damage.
01 September 2022
Novo Nordisk announced an agreement to acquire Forma Therapeutics.
Novo Nordisk and Forma Therapeutics announced that they have agreed to the acquisition of Forma Therapeutics by Novo Nordisk for $20 per share in cash. Novo Nordisk has agreed to pay $1.1 billion for this acquisition.
With this acquisition, Novo Nordisk aims to expand its presence in sickle cell disease and other rare blood disorders.